Cell therapies, ranging from CAR-T cells to stem-cell-based approaches, are emerging as a transformative therapeutic modality. Panelists will examine this emerging landscape and discuss a range of key topics. What drives differentiation in this space given the high number of competing technologies? How will the uptake of autologous cell therapies and allogeneic versions evolve? When will the regenerative medicine market mature?
Guests:
Marcela Maus, MD, PhD, Director, Cellular Immunotherapy Program, Cancer Center, MGH; Associate Professor, Medicine, HMS
Christina Coughlin, MD, PhD, CEO, CytoImmune
Rachel Haurwitz, PhD, President & CEO, Caribou Biosciences
Nick Leschly, CEO, 2seventy bio
Dhvanit Shah, PhD, President & CEO, Garuda Therapeutics
Rusty Williams, MD, PhD, Chairman & CEO, Walking Fish Therapeutics